{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:59:22Z","timestamp":1791644362099,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023YFS0027"],"award-info":[{"award-number":["2023YFS0027"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>After propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants aged 59 (51\u201364) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid\u2013base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Individuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-023-03080-6","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T18:02:00Z","timestamp":1697824920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank"],"prefix":"10.1186","volume":"21","author":[{"given":"Yu","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"3080_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrgastro.2014.232","volume":"12","author":"ME Rinella","year":"2015","unstructured":"Rinella ME, Sanyal AJ. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015;12:65\u20136.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3080_CR2","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263\u201373.","journal-title":"JAMA"},{"key":"3080_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"3080_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.4155\/fmc-2019-0003","volume":"11","author":"S Ballestri","year":"2019","unstructured":"Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Fut Med Chem. 2019;11:2171\u201392.","journal-title":"Fut Med Chem"},{"key":"3080_CR5","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","volume":"20","author":"Z Liu","year":"2022","unstructured":"Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, et al. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clin Gastroenterol Hepatol. 2022;20:e855\u201375.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3080_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","volume":"17","author":"S Chen","year":"2023","unstructured":"Chen S, Pang J, Huang R, Xue H, Chen X. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hep Intl. 2023;17:595\u2013605.","journal-title":"Hep Intl"},{"key":"3080_CR7","doi-asserted-by":"crossref","unstructured":"Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabol: Clin Exp. 2021;123:154868.","DOI":"10.1016\/j.metabol.2021.154868"},{"key":"3080_CR8","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19:2138-2147.e2110.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3080_CR9","doi-asserted-by":"crossref","unstructured":"Liu Z, Lin C, Suo C, Zhao R, Jin L, Zhang T, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabol: Clin Exp. 2022;127:154955.","DOI":"10.1016\/j.metabol.2021.154955"},{"key":"3080_CR10","first-page":"1034","volume":"10","author":"Q Yu","year":"2022","unstructured":"Yu Q, He R, Jiang H, Wu J, Xi Z, He K, et al. Association between metabolic dysfunction-associated fatty liver disease and cognitive impairment. J Clin Transl Hepatol. 2022;10:1034\u201341.","journal-title":"J Clin Transl Hepatol"},{"key":"3080_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12072-022-10424-6","volume":"17","author":"J Chen","year":"2023","unstructured":"Chen J, Dan L, Tu X, Sun Y, Deng M, Chen X, et al. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn\u2019s disease but not Ulcerative Colitis: a prospective cohort study. Hep Intl. 2023;17:202\u201314.","journal-title":"Hep Intl"},{"key":"3080_CR12","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/jcsm.12754","volume":"12","author":"HS Chun","year":"2021","unstructured":"Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, et al. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2021;12:1168\u201378.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3080_CR13","doi-asserted-by":"crossref","unstructured":"Jensen AB, Moseley PL, Oprea TI, Elles\u00f8e SG, Eriksson R, Schmock H, et al. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun. 2014;5:4022.","DOI":"10.1038\/ncomms5022"},{"key":"3080_CR14","doi-asserted-by":"crossref","unstructured":"Siggaard T, Reguant R, J\u00f8rgensen IF, Haue AD, Lademann M, Aguayo-Orozco A, et al. Disease trajectory browser for exploring temporal, population-wide disease progression patterns in 7.2 million Danish patients. Nat Commun. 2020;11:4952.","DOI":"10.1038\/s41467-020-18682-4"},{"key":"3080_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13058-019-1181-5","volume":"21","author":"H Yang","year":"2019","unstructured":"Yang H, Pawitan Y, He W, Eriksson L, Holowko N, Hall P, et al. Disease trajectories and mortality among women diagnosed with breast cancer. Breast Cancer Res. 2019;21:95.","journal-title":"Breast Cancer Res"},{"key":"3080_CR16","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1038\/s41380-021-01170-6","volume":"26","author":"X Han","year":"2021","unstructured":"Han X, Hou C, Yang H, Chen W, Ying Z, Hu Y, et al. Disease trajectories and mortality among individuals diagnosed with depression: a community-based cohort study in UK Biobank. Mol Psychiatry. 2021;26:6736\u201346.","journal-title":"Mol Psychiatry"},{"key":"3080_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(12)60404-8","volume":"379","author":"R Collins","year":"2012","unstructured":"Collins R. What makes UK Biobank special? Lancet (London, England). 2012;379:1173\u20134.","journal-title":"Lancet (London, England)"},{"key":"3080_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","volume":"186","author":"A Fry","year":"2017","unstructured":"Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017;186:1026\u201334.","journal-title":"Am J Epidemiol"},{"key":"3080_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.","journal-title":"BMC Gastroenterol"},{"key":"3080_CR20","doi-asserted-by":"crossref","unstructured":"Castellana M, Donghia R, Guerra V, Procino F, Lampignano L, Castellana F, et al. Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. A meta-analysis. J Clin Med. 2021;10(9):1877.","DOI":"10.3390\/jcm10091877"},{"key":"3080_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (Baltimore, MD). 2007;45:846\u201354.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"3080_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/pubmed\/fdr054","volume":"34","author":"EM Burns","year":"2012","unstructured":"Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, et al. Systematic review of discharge coding accuracy. J Public Health (Oxf). 2012;34:138\u201348.","journal-title":"J Public Health (Oxf)"},{"key":"3080_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203\u20139.","journal-title":"Nature"},{"key":"3080_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7-TMC4 Variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150:1219-1230.e1216.","journal-title":"Gastroenterology"},{"key":"3080_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7: e1001324.","journal-title":"PLoS Genet"},{"key":"3080_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybj\u00e6rg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352\u20136.","journal-title":"Nat Genet"},{"key":"3080_CR27","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461\u20135.","journal-title":"Nat Genet"},{"key":"3080_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology (Baltimore, MD). 2019;70:1457\u201369.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"3080_CR29","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.2633","volume":"4","author":"G Cao","year":"2016","unstructured":"Cao G, Yi T, Liu Q, Wang M, Tang S. Alcohol consumption and risk of fatty liver disease: a meta-analysis. PeerJ. 2016;4: e2633.","journal-title":"PeerJ"},{"key":"3080_CR30","first-page":"568","volume":"34","author":"K Wijarnpreecha","year":"2021","unstructured":"Wijarnpreecha K, Aby ES, Panjawatanan P, Lapumnuaypol K, Cheungpasitporn W, Lukens FJ, et al. Modest alcohol consumption and risk of advanced liver fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Gastroenterol. 2021;34:568\u201374.","journal-title":"Ann Gastroenterol"},{"key":"3080_CR31","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.3350\/cmh.2022.0393","volume":"29","author":"H Oh","year":"2023","unstructured":"Oh H, Sohn W, Cho YK. The effects of moderate alcohol consumption on non-alcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S261-s267.","journal-title":"Clin Mol Hepatol"},{"key":"3080_CR32","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u201369.","journal-title":"N Engl J Med"},{"key":"3080_CR33","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, Roelstraete B, Hagstr\u00f6m H, Sundstr\u00f6m J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71:1867\u201375.","journal-title":"Gut"},{"key":"3080_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3080_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","volume":"28","author":"P Dietrich","year":"2014","unstructured":"Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637\u201353.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3080_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.gtc.2019.10.002","volume":"49","author":"J Wattacheril","year":"2020","unstructured":"Wattacheril J. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gastroenterol Clin North Am. 2020;49:141\u20139.","journal-title":"Gastroenterol Clin North Am"},{"key":"3080_CR37","first-page":"452","volume":"11","author":"L Liu","year":"2023","unstructured":"Liu L, Yin M, Gao J, Yu C, Lin J, Wu A, et al. Intestinal barrier function in the pathogenesis of nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2023;11:452\u20138.","journal-title":"J Clin Transl Hepatol"},{"key":"3080_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","volume":"12","author":"J Behary","year":"2021","unstructured":"Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021;12:187.","journal-title":"Nat Commun"},{"key":"3080_CR39","doi-asserted-by":"publisher","first-page":"5833857","DOI":"10.1155\/2021\/5833857","volume":"2021","author":"F Wang","year":"2021","unstructured":"Wang F, Cen Z, Liu Z, Gan J, Zhang X, Cui Q, et al. High-fat diet-induced fatty liver is associated with immunosuppressive response during sepsis in mice. Oxid Med Cell Longev. 2021;2021:5833857.","journal-title":"Oxid Med Cell Longev"},{"key":"3080_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10:329\u201338.","journal-title":"J Clin Transl Hepatol"},{"key":"3080_CR41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/hepr.13790","volume":"52","author":"K Mori","year":"2022","unstructured":"Mori K, Tanaka M, Higashiura Y, Hanawa N, Ohnishi H, Furuhashi M. High fatty liver index is an independent predictor of ischemic heart disease during a 10-year period in a Japanese population. Hepatol Res. 2022;52:687\u201398.","journal-title":"Hepatol Res"},{"key":"3080_CR42","doi-asserted-by":"crossref","unstructured":"Shea S, Lionis C, Kite C, Atkinson L, Chaggar SS, Randeva HS, et al. Non-Alcoholic Fatty Liver Disease (NAFLD) and potential links to depression, anxiety, and chronic stress. Biomedicines. 2021;9(11):1697.","DOI":"10.3390\/biomedicines9111697"},{"key":"3080_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.psym.2018.09.001","volume":"60","author":"K Karaivazoglou","year":"2019","unstructured":"Karaivazoglou K, Kalogeropoulou M, Assimakopoulos S, Triantos C. Psychosocial issues in pediatric nonalcoholic fatty liver disease. Psychosomatics. 2019;60:10\u20137.","journal-title":"Psychosomatics"},{"key":"3080_CR44","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.cgh.2017.11.026","volume":"16","author":"YC Hwang","year":"2018","unstructured":"Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men. Clin Gastroenterol Hepatol. 2018;16:1131-1137.e1135.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3080_CR45","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168\u201385.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3080_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.584396","volume":"7","author":"Y Lin","year":"2020","unstructured":"Lin Y, Gong X, Li X, Shao C, Wu T, Li M, et al. Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years\u2019 cross-sectional multicenter study in China. Front Med. 2020;7: 584396.","journal-title":"Front Med"},{"key":"3080_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","volume":"12","author":"CM Lewis","year":"2020","unstructured":"Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome medicine. 2020;12:44.","journal-title":"Genome medicine"},{"key":"3080_CR48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","volume":"20","author":"A De Vincentis","year":"2022","unstructured":"De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol. 2022;20:658\u201373.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3080_CR49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","volume":"74","author":"C Bianco","year":"2021","unstructured":"Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74:775\u201382.","journal-title":"J Hepatol"},{"key":"3080_CR50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3350\/cmh.2021.0310","volume":"28","author":"T Kawaguchi","year":"2022","unstructured":"Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28:150\u201363.","journal-title":"Clin Mol Hepatol"},{"key":"3080_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","volume":"38","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38:251\u201360.","journal-title":"Curr Opin Gastroenterol"},{"key":"3080_CR52","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ahmed A, Despr\u00e9s JP, Jha V, Halford JCG, Wei Chieh JT, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6:743\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3080_CR53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, MD). 2018;67:328\u201357.","journal-title":"Hepatology (Baltimore, MD)"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03080-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T16:29:52Z","timestamp":1700497792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03080-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3080"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03080-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval of UK Biobank study was approved by NHS National Research Ethics Service (16\/NW\/0274). The experimental protocols were established according to the ethical guidelines of the Helsinki Declaration. Written informed consent was obtained from individual or guardian participants. All methods were carried out in accordance with guidelines and regulations developed by UK Biobank. Data usage was approved by the Human Ethical Committee of the West China Hospital of Sichuan University (2021\u2013601).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"398"}}